Agilent Alissa to QCI Interpret: How can your lab reduce the stress and...
Description
In 2023, Agilent announced the discontinuation of their Alissa Interpret clinical informatics platform by the end of 2024. As a result, many of their current customers need to transition to a new variant interpretation and reporting software within a tight timeframe. However, when evaluating new interpretation solutions, clinical labs must consider a variety of factors, including:
Content quality for clinical reporting
Flexibility to adapt current workflows to a new platform
Retaining historical content and comments
Ease of personnel training
In this webinar, learn about QCI Interpret, a panel- and sequencer-agnostic clinical informatics platform for NGS variant interpretation and reporting of germline and somatic tests. Our experts will address the concerns of current Alissa users and discuss what sets QCI Interpret apart from other interpretation solutions. In addition, we will show you how seamless it is to transition to QCI Interpret, as well as provide a live demonstration of the industry-leading and reliable software that has been used to analyze and interpret more than 3.5 million patient test cases worldwide.
United States
